Provenance Record

Clear, well-structured News piece (666 words, within the 400-1200 News range). Overview / What We Know / What We Don't Know / Analysis structure cleanly separates the verified mechanism from the preclinical caveats. Technical concepts (GRK2 aggregation, mitochondrial energy supply, the amyloid feedback loop, compound 10) are explained accessibly without overclaiming.

All four source snapshots read from disk and verified. source-0 (ETH Zurich, status 200): confirms GRK2 role, aggregates damaging mitochondria, compound 10 preventing aggregation, fewer grey hairs / heart-function effect, patent applied for, company search, and the verbatim quote 'It took so long simply because everything takes so long in Alzheimer's research.' source-1 (ScienceDaily, status 200): confirms the verbatim quote 'The GRK2 aggregates block the pores of the mitochondria, reducing the amount of energy they can supply and leading to a situation of stress inside the cells,' attributed to Ursula Quitterer, Professor of Molecular Pharmacology at ETH Zurich; confirms Cell Reports Medicine publication and the 'nearly two decades' timeline. source-2 (Neuroscience News, status 200, fetched via Archive.org fallback): confirms June 8 2026 date, the mechanism distinct from amyloid plaques, the vicious-circle/feedback-loop framing, and the Ain Shams University Hospital (Cairo) tumour-surgery tissue provenance. source-3 (News-Medical, status 200): confirms the inactivated GRK2 form accumulating/aggregating, 'the typical death of nerve cells seen in dementia is significantly slower, and the animals survive for longer' (faithfully paraphrased, not in quote marks), 'research that began almost 20 years ago' (supports 'nearly two decades'), and 'Quitterer and ETH Zurich are looking for a company' (supports 'no clinical development partner yet in place'). Every cited attribution maps to a snapshot that supports it.

No fabrications or misattributions detected. Both direct quotes appear verbatim in their cited snapshots with the correct speaker (Ursula Quitterer) and correct title (Professor of Molecular Pharmacology at ETH Zurich). 'compound 10', 'GRK2' and 'Quitterer' are spelled verbatim throughout. The internal cross-reference to the April 2026 semaglutide article resolves to an existing published article. The Cell Reports Medicine primary paper (cell.com/Elsevier) was NOT cited as a source and is therefore not a failed snapshot; the article correctly relies only on the four accessible press releases and contains NO paper-internal efficacy numbers or percentages — a deliberate and correct handling of the inaccessible primary source under Rule 9 and Rule 2/5i. The only numeric tokens in the body are the June 8 2026 publication date, the compound name 'compound 10', and the cross-reference URL.

High-quality, fully verified preclinical science report. All four sources read and confirmed, both quotes verbatim with correct speaker and title, preclinical framing sound, no leaked statistics, internal cross-reference resolves. APPROVE.